EnVivo Appoints Several Leaders to Its Scientific Advisory Board.
Watertown, MA – December 22, 2003 – EnVivo Pharmaceuticals, Inc., a privately held biopharmaceuticals company, announced today that Dr. Leslie Benet and Dr. Don Price will join the company’s distinguished Scientific Advisory Board.
Dr. Leslie Benet is Professor and former Chair (1978-1998) of Biopharmaceutical Sciences at the University of California, San Francisco, and Chairman of the Boards of AvMax Inc. and OxoN Medica Inc. An internationally recognized authority on drug bioavailability and pharmacokinetics, Dr. Benet has recently published widely on the interplay of drug transporters and metabolic enzymes as they affect the bioavailability, distribution and elimination of pharmaceuticals. He is the recipient of 5 honorary doctorates and is an elected member of the Institute of Medicine of the U.S. National Academy of Sciences.
Dr. Donald Price is Professor of Pathology, Neurology, and Neuroscience, Vice Chair for Research in the Department of Pathology and Director of the Division of Neuropathology at The Johns Hopkins University School of Medicine. He is also Director of the Alzheimer’s Disease Research Center at The Johns Hopkins Hospital and The Johns Hopkins University School of Medicine. Dr. Price has made major contributions to the understanding of a variety of human neurodegenerative diseases. He is an author of over 400 publications in scientific journals and over 200 book chapters/reviews. Of particular importance to the field of neurodegeneration are the development and analysis of animal models and the investigation of experimental therapeutic strategies that prepare the way for translation of basic science discoveries to treatments of humans with neurological illnesses. Dr. Price is a member of several professional societies, and has received numerous honors and awards including two Javits Neuroscience Investigator Merit Awards from the NINDS and a Leadership in Alzheimer’s Disease Award from the National Institute of Aging.
"The addition of Dr. Benet and Dr. Price to our Board enhances our ability to build a leading biopharmaceutical company based on cutting edge scientific advances," said Dr. David Lowe, EnVivo’s President and Chief Executive Officer. "Their experience will help EnVivo realize its mission of creating therapeutics for neurodegenerative diseases and other CNS disorders."
Dr. Benet and Dr. Price join distinguished thought leaders on EnVivo’s Scientific Advisory Board including Dr. Gregory L. Verdine, Erving Professor of Chemistry at Harvard University, Dr. J. Lawrence Marsh, Professor of Developmental and Cell Biology at University of California, Irvine, Dr. Leslie Thompson, Assistant Professor of Psychiatry and Human Behavior at Univesity of California, Irvine, Dr. Norbert Perrimon, Professor of Genetics at the Harvard Medical School, Dr. Peter T. Lansbury, Associate Professor of Neurology at the Harvard Medical School. They serve on the Scientific Advisory Board alongside the scientific founders of EnVivo—Dr. Juan Botas, Assistant Professor of Human Genetics at Baylor College of Medicine, Dr. Cayetano González, Cellular Proliferation Group, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain Dr. Zach W. Hall, Senior Associate Dean for Research, Keck School of Medicine, UCLA, Dr. Luis Serrano, Head, Structure & Biocomputing program, European Molecular Biology Laboratory, and Dr. Huda Zoghbi, Professor, Human Genetics, Neurology, Neuroscience and Pediatrics, Baylor College of Medicine.
About EnVivo Pharmaceuticals, Inc.: Headquartered in Watertown, MA, EnVivo Pharmaceuticals is a privately held biopharmaceutical company dedicated to discovering and developing therapeutics for disorders of the brain. EnVivo has created a new paradigm in drug discovery by using industrialized in vivo screening of disease models in simple organisms. Its technology greatly improves and accelerates the drug discovery process because it specifically assays for changes in clinically relevant symptoms, such as the organism’s motor function. Because the screen detects improvements in disease symptoms, it does not depend on prior understanding of the disease mechanism. EnVivo’s technology is particularly suitable for the CNS as it screens for drugs that can act at multiple cellular and molecular sites within the complex neural circuits that regulate behavior. For more information about EnVivo, please visit www.envivopharma.com.
For additional information, please contact:
Media Relations
Tel: 617-563-5800
